Scienture Holdings Inc SCNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
-
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
-
Scienture Holdings, Inc. Announces Reverse Stock Split
-
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
-
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
-
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
-
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Trading Information
- Previous Close Price
- $3.35
- Day Range
- $3.21–3.68
- 52-Week Range
- $3.21–65.00
- Bid/Ask
- $3.39 / $3.97
- Shares Outstanding
- 1.64M
- Market Cap
- $5.55M
- Volume/Avg
- 2,935 / 184,582
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.scienture.com
Valuation
|
Metric
|
SCNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.08 |
Price/Sales | 3.83 |
Price/Cash Flow | — |
Price/Earnings
SCNX
Financial Strength
|
Metric
|
SCNX
|
|---|---|
Quick Ratio | 2.83 |
Current Ratio | 3.04 |
Interest Coverage | −12.19 |
Quick Ratio
SCNX
Profitability
|
Metric
|
SCNX
|
|---|---|
Return on Assets (Normalized) | −13.20% |
Return on Equity (Normalized) | −16.86% |
Return on Invested Capital (Normalized) | −12.86% |
Return on Assets
SCNX
Pharmaceutical Retailers Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| JD Health International Inc
JDHIF
| — | LOCK|@@PF | $15B | |||
| JD Health International Inc ADR
JDHIY
| — | LOCK|tjG^! | $15B | |||
| Raia Drogasil SA ADR
RADLY
| — | LOCK|cJ>bW | $7B | |||
| Alibaba Health Information Technology Ltd
ALBHF
| — | LOCK|SF@>x | $6B | |||
| Alibaba Health Information Technology Ltd ADR
ALBBY
| — | LOCK|F!HZX | $6B | |||
| Clicks Group Ltd
CCKRF
| — | LOCK|DrbBC | $3B | |||
| Clicks Group Ltd ADR
CLCGY
| — | LOCK|kM?> | $3B | |||
| COSMOS Pharmaceutical Corp
CSMYF
| — | LOCK|G< | $3B | |||
| Redcare Pharmacy NV ADR
SAEYY
| — | LOCK|!XD | $2B | |||
| High Tide Inc
HITI
| — | LOCK|d? | $227M |
United States